TY - JOUR
T1 - Statins and the Liver
AU - Herrick, Cynthia
AU - Bahrainy, Samira
AU - Gill, Edward A.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.
AB - Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.
KW - Chronic liver disease
KW - Dyslipidemia
KW - Hepatic transaminases
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=84958158427&partnerID=8YFLogxK
U2 - 10.1016/j.ecl.2015.09.008
DO - 10.1016/j.ecl.2015.09.008
M3 - Review article
C2 - 26893001
AN - SCOPUS:84958158427
SN - 0889-8529
VL - 45
SP - 117
EP - 128
JO - Endocrinology and Metabolism Clinics of North America
JF - Endocrinology and Metabolism Clinics of North America
IS - 1
ER -